Livforsakringsbolaget Skandia Omsesidigt Lowers Holdings in Regeneron Pharmaceuticals, Inc. $REGN

Key Points

• Livforsakringsbolaget Skandia Omsesidigt reduced its stake in Regeneron Pharmaceuticals by 92.3%, selling 10,460 shares to hold 872 shares valued at $457,000.
• Regeneron Pharmaceuticals reported a quarterly earnings per share (EPS) of $12.89, significantly exceeding expectations and achieving a net margin of 31.37%.
• The company has recently announced a quarterly dividend of $0.88 per share, resulting in an annualized yield of 0.6%.

Livforsakringsbolaget Skandia Omsesidigt lowered its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 92.3% in the second quarter, according to its most recent disclosure with the SEC. The firm owned 872 shares of the biopharmaceutical company's stock after selling 10,460 shares during the period. Livforsakringsbolaget Skandia Omsesidigt's holdings in Regeneron Pharmaceuticals were worth $457,000 as of its most recent filing with the SEC.

Other hedge funds have also recently bought and sold shares of the company. Marietta Wealth Management LLC raised its position in shares of Regeneron Pharmaceuticals by 30.2% in the first quarter. Marietta Wealth Management LLC now owns 10,778 shares of the biopharmaceutical company's stock valued at $6,836,000 after buying an additional 2,501 shares in the last quarter. Sepio Capital LP raised its position in shares of Regeneron Pharmaceuticals by 33.1% in the first quarter. Sepio Capital LP now owns 3,389 shares of the biopharmaceutical company's stock valued at $2,150,000 after buying an additional 842 shares in the last quarter. GAMMA Investing LLC raised its position in shares of Regeneron Pharmaceuticals by 89,825.0% in the first quarter. GAMMA Investing LLC now owns 815,620 shares of the biopharmaceutical company's stock valued at $517,291,000 after buying an additional 814,713 shares in the last quarter. China Universal Asset Management Co. Ltd. raised its position in shares of Regeneron Pharmaceuticals by 3.9% in the first quarter. China Universal Asset Management Co. Ltd. now owns 25,629 shares of the biopharmaceutical company's stock valued at $16,255,000 after buying an additional 955 shares in the last quarter. Finally, KBC Group NV raised its position in shares of Regeneron Pharmaceuticals by 9.4% in the first quarter. KBC Group NV now owns 149,440 shares of the biopharmaceutical company's stock valued at $94,779,000 after buying an additional 12,793 shares in the last quarter. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on the stock. Wells Fargo & Company downgraded shares of Regeneron Pharmaceuticals from an "overweight" rating to an "equal weight" rating and set a $580.00 price target for the company. in a research report on Friday, August 1st. Rothschild & Co Redburn initiated coverage on shares of Regeneron Pharmaceuticals in a research report on Thursday, August 14th. They set a "buy" rating and a $890.00 price objective for the company. JPMorgan Chase & Co. lowered their price objective on shares of Regeneron Pharmaceuticals from $950.00 to $800.00 and set an "overweight" rating for the company in a research report on Monday, June 9th. Guggenheim boosted their price objective on shares of Regeneron Pharmaceuticals from $810.00 to $815.00 and gave the company a "buy" rating in a research report on Friday, August 1st. Finally, Royal Bank Of Canada boosted their price objective on shares of Regeneron Pharmaceuticals from $688.00 to $695.00 and gave the company a "sector perform" rating in a research report on Monday, August 4th. Three analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating, six have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $817.67.

Regeneron Pharmaceuticals Trading Down 1.1%

REGN stock traded down $6.72 during midday trading on Friday, hitting $591.99. The stock had a trading volume of 2,177,965 shares, compared to its average volume of 1,100,130. The firm has a market cap of $62.75 billion, a P/E ratio of 14.92, a price-to-earnings-growth ratio of 1.96 and a beta of 0.35. The company has a current ratio of 4.60, a quick ratio of 3.72 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals, Inc. has a 1-year low of $476.49 and a 1-year high of $1,154.56. The business has a fifty day moving average price of $567.29 and a two-hundred day moving average price of $576.47.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last posted its earnings results on Friday, August 1st. The biopharmaceutical company reported $12.89 earnings per share for the quarter, topping analysts' consensus estimates of $8.43 by $4.46. Regeneron Pharmaceuticals had a net margin of 31.37% and a return on equity of 15.06%. The company had revenue of $3.68 billion for the quarter, compared to analyst estimates of $3.30 billion. During the same quarter in the prior year, the business posted $11.56 EPS. The firm's revenue was up 3.6% compared to the same quarter last year. On average, sell-side analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, September 3rd. Investors of record on Monday, August 18th were issued a $0.88 dividend. The ex-dividend date of this dividend was Monday, August 18th. This represents a $3.52 annualized dividend and a yield of 0.6%. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is 8.87%.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.